Furosemide

(Furosemide Injection)

VValidus Pharmaceuticals

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Pulmonary Edema

NCT05276219

Q3 2028

Phase 2Active, not recruiting

Prostate Adenocarcinoma

NCT05779943

Q4 2028

ApprovedRecruiting

Acute Kidney Injury

NCT06229990

Clinical

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

Strategy to Reduce Bladder Activity With RhPSMA 7.3: Comparison of 18F-RhPSMA 7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Active, not recruiting·EEmory University·Phase 2·NCT05779943·20 enrolled

Acute Kidney Injury1 trial

Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury (FST-LIBERATE)

Recruiting·CChiang Mai University·Approved·NCT06229990·88 enrolled

Pulmonary Edema1 trial

Vasodilatation or Loop-Diuretics for Initial Treatment of Pulmonary Congestion Due to Acute Heart Failure - A Randomized Placebo-Controlled Trial

Recruiting·JJohannes Grand·Approved·NCT05276219·1,041 enrolled

Kidney Function1 trial

Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function

Completed·KKing Chulalongkorn Memorial Hospital·Preclinical·NCT03071536·360 enrolled

Regulatory

FDA Approval Timeline[3]

Jan 1, 1982

LASIX

NDA NDA016363

Jan 1, 1982

LASIX

NDA NDA016273

Jan 1, 1982

FUROSEMIDE

NDA NDA018569

Jan 1, 1982

FUROSEMIDE

NDA NDA018025

Jan 1, 1982

LASIX

NDA NDA017688

Jan 1, 1982

FUROSEMIDE

NDA NDA018487

Jan 1, 1982

FUROSEMIDE

NDA NDA018267

Feb 26, 1982

FUROSEMIDE

NDA NDA018420

May 14, 1982

FUROSEMIDE

NDA NDA018369

May 28, 1982

FUROSEMIDE

NDA NDA018667

Jul 20, 1982

FUROSEMIDE

NDA NDA018670

Jul 27, 1982

FUROSEMIDE

NDA NDA018415

Jul 30, 1982

FUROSEMIDE

NDA NDA018507

Jan 31, 1983

FUROSEMIDE

NDA NDA018419

Jun 28, 1983

FUROSEMIDE

NDA NDA018868

Nov 10, 1983

FUROSEMIDE

NDA NDA018823

Nov 29, 1983

FUROSEMIDE

NDA NDA018790

Nov 30, 1983

FUROSEMIDE

NDA NDA018579

Nov 30, 1983

FUROSEMIDE

NDA NDA018413

Feb 28, 1984

FUROSEMIDE

NDA NDA018753

May 22, 1984

FUROSEMIDE

NDA NDA018902

Jun 26, 1984

FUROSEMIDE

NDA NDA018370

Jul 30, 1984

FUROSEMIDE

NDA NDA018750

Aug 13, 1984

FUROSEMIDE

NDA NDA019036

Oct 7, 2022

FUROSCIX

NDA NDA209988

Oct 7, 2025

LASIX ONYU

NDA NDA217294

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Furosemide Injection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Furosemide Injection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA217294). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Validus Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: VValidus Pharmaceuticals

Furosemide

Expected Milestones

Q2 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Prostate Adenocarcinoma1 trial

Acute Kidney Injury1 trial

Pulmonary Edema1 trial

Kidney Function1 trial

FDA Approval Timeline[3]

References

Drug Info

Quick Facts

Related News